Skip to main content
. 2023 Nov 21;42(12):1391–1402. doi: 10.1200/JCO.22.02912

TABLE 2.

Tumor Responses as Assessed by the BIRC

End Point RC48-C005 (n = 43) RC48-C009 (n = 64) Overall (n = 107)
Confirmed objective response rate, % (95% CI) 51.2 (35.5 to 66.7) 50.0 (37.2 to 62.8) 50.5 (40.6 to 60.3)
 IHC2+ and FISH+ or IHC3+ 60.0 (36.1 to 80.9) 64.0 (42.5 to 82.0) 62.2 (46.5 to 76.2)a
 IHC2+ and FISH– 40.0 (19.1 to 63.9) 39.4 (22.9 to 57.9) 39.6 (26.5 to 54.0)a
 IHC2+ and FISH unknown 66.7 (9.4 to 99.2) 50.0 (11.8 to 88.2) 55.6 (21.2 to 86.3)a
Best overall response, No. (%) (95% CI)
 Complete response 0 (0.0) (0.2 to 6.6) 2 (3.1) (0.4 to 10.8) 2 (1.9) (0.2 to 6.6)
 Partial response 22 (51.2) (38.8 to 58.5) 30 (46.9) (34.3 to 59.8) 52 (48.6) (38.8 to 58.5)
 Stable disease 17 (39.5) (23.1 to 41.5) 17 (26.6) (16.3 to 39.1) 34 (31.8) (23.1 to 41.5)
 Progressive disease 3 (7.0) (8.1 to 22.1) 12 (18.8) (10.1 to 30.5) 15 (14.0) (8.1 to 22.1)
 Not evaluable 1 (2.3) (1.0 to 9.3) 3 (4.7) (1.0 to 13.1) 4 (3.7) (1.0 to 9.3)
DCR, No. (%) (95% CI) 39 (90.7) (77.9 to 97.4) 49 (76.6) (64.3 to 86.2) 88 (82.2) (73.7 to 89.0)
Duration of response, months (95% CI) 7.0 (4.7 to 12.4) 8.3 (4.3 to 12.6) 7.3 (5.7 to 10.8)
PFS
 Median, months (95% CI) 6.9 (5.4 to 9.0) 5.3 (4.0 to 7.2) 5.9 (4.3 to 7.2)
 12-month rate, % (95% CI) 23.6 (11.5 to 38.1) 25.3 (15.0 to 36.9) 24.7 (16.5 to 33.7)
OS
 Median, months (95% CI) 13.9 (9.1 to NE) 14.8 (8.7 to 18.6) 14.2 (9.7 to 18.8)
 18-month rate, % (95% CI) 46.3 (30.9 to 60.3) 39.6 (27.2 to 51.6) 42.2 (32.5 to 51.5)
OS follow-up, months, median 19.6 23.4 20.5

Abbreviations: BIRC, blinded independent review committee; DCR, disease control rate; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NE, not estimable; OS, overall survival; PFS, progression-free survival.

a

There is no statistical difference among the three subgroups for C005, C009, and overall with P = .4441, P = .1649, and P = .0798, respectively.